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safety conditions worsen to 20%. Therefore there is a need to organize trainings for 
administrative staffs and workers.
PHP54
PHarmacoeconomic researcH and aPPlication in 10 asian countries 
Between 2003 and 2013: a systematic review
Pham V.N.H.1, Hoang T.M.2, Postma M.J.3
1Hanoi University of Pharmacy, Ha Noi, Vietnam, 2School of Medicine and Pharmacy, Vietnam 
National University, Ha Noi, Vietnam, 3University of Groningen, Groningen, The Netherlands
Objectives: To describe and analyze specific aspects of pharmacoeconomic 
research and application in 10 Asian countries in recent years from 2003 to 
2013. MethOds: Our study concentrated on 10 Asian countries, including China, 
Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand 
and Vietnam. Literature was collected and reviewed systematically from United 
States National Library of Medicine- PubMed. Grey literature was also taken into 
account. After screening, a total of 268 pharmacoeconomic research articles and 
38 pharmacoeconomic application studies were included. This review followed the 
Cochrane systematic review guidelines and PRISMA flow diagram. Publication was 
analyzed by regions, economic evaluation techniques used, drug groups analyzed. 
The status of these pharmacoeconomic studies was identified with options being: 
for scientific interest, undertaken to support reimbursement issues directly or per-
formed in the framework of clinical guidelines or formularies. Results: There is 
an increasing in the number of pharmacoeconomic studies in Asian countries in 
the later period (2008-2013) compared with the first five years considered (2003-
2007). Most pharmacoeconomic studies were carried out in Japan (26%), China (22%), 
Thailand (15%), Taiwan (12%) and South Korea (10%). Cost-effectiveness analysis 
and cost-utility analysis were the most popular economic evaluation techniques 
used in 84% of total studies published. Antiinfectives for systemic use, antineo-
plastic and immunomodulating agents, nervous system and cardiovascular system 
drug groups were mostly researched and accounted for 41.79%, 19.78%, 10.45% and 
8.21%, respectively. Status of pharmacoeconomics applications varied among coun-
tries. cOnclusiOns: The number of pharmacoeconomic studies in Asia increased 
from 2008 onwards. The studies were mostly carried out in 5 specific countries (85% 
total) and concentrated to 4 specific drug groups. Types of pharmacoeconomics 
applications and research foci differ considerably amongst Asian countries.
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Objectives: The purpose of this study was to understand the drivers of the pricing 
premiums granted for submitting local RCT and / or local pharmacoeconomics (PE) 
data during the Taiwanese reimbursement assessment process. MethOds: The 11 
products that submitted local RCT and / or local PE data in their reimbursement 
submission to the NHIA between January 2012 and March 2014 were analysed in 
this study. Results: Of the 6 products that submitted local RCT data, 3 received 
the maximum 10% pricing premium for submitting these data. Abatacept was not 
granted any premium for not being a new molecule and benidipine hydrochloride 
was not granted any premium since its price comparator was an existing product 
that was already priced based on local data. Sorafenib has yet to receive a decision 
for the premium granted. Of the 7 products that submitted local PE data, 5 received 
a premium. 2 received a 1% and 2% premium respectively for submitting data with 
high uncertainty, 1 received a 2% premium for using inappropriate comparator dos-
age in the analysis, and 2 received a 5% premium for submitting data that were well 
accepted by the NHIA. 2 products did not receive any premium, as their data were 
considered to be incomplete or inappropriate. All of the submissions highlighted the 
product’s cost-effectiveness against the comparator. cOnclusiOns: A 10% pricing 
premium through local RCT data is likely achievable as long as the product with 
local RCT data is a new molecule whose comparator has not been priced based on 
its local data. On the other hand, achieving the maximum 10% pricing premium 
for submitting local PE data seems difficult to achieve; as of now, a 5% premium 
seems to be the maximum achievable. A premium as low as 1-2% is likely if there 
is any uncertainty in the data.
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Objectives: In Taiwan, the Second-Generation National Health Insurance (2G-NHI) 
Act was implemented since Jan. 1st, 2013. Thereafter, listing and reimbursement of 
new products are 2-stage assessments performed by the Expert Advisory Committee 
(EAC) and Pharmaceutical Benefits Reimbursement Scheme (PBRS) of National 
Health Insurance Administration (NHIA). EAC primarily evaluates clinical compara-
tive effectiveness and safety of new products, and assessments are rated as Category 
1 (substantial improvement), 2A (moderate improvement) or 2B (similar) compared 
to current standard therapy which are also used for pricing comparators. PBRS fur-
ther appraises the EAC’s suggestions and make final reimbursement recommenda-
tions. The objective of this study was to analyze the trends of the PBRS appraisals 
from Jan. 2013 to Feb. 2014 since implementation of the 2G-NHI Act. MethOds: 
A total of 33 new drugs underwent EAC assessments and PBRS appraisals were 
reviewed for their Categories. Further analysis was conducted to understand the 
trends based on the therapeutic indications and comparators. Results: There were 
21 new drugs granted reimbursement recommendations from PBRS joint meeting. 
Approximately 57% of them were rated as Category 2B, 38% as Category 2A, and only 
5% as Category 1. A new trend revealed that Category 2B new drugs were easier to 
be listed and reimbursed. The only Category 1 new product is an orphan drug in 
western countries used to mobilize haematopoietic stem cells for autologous trans-
and most important step that causes properly usage of such products as well as 
preventing the side effects from abuse of such products and for highly consumed 
products such as sunscreen cares and depilatories.
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Objectives: To implement the PSUR system in all wards of hospital. Reporting of 
PSURs for all the running newly launched drugs since 2011 in hospital periodically 
to DCG (I), New Delhi and assessment of the PSUR system functioning in the hospi-
tal. MethOds: Prospective observational study. Drug safety reporting either manual 
or through online portal. Preparation and submission of PSURs as per Schedule Y 
of drugs and Cosmetics act, India. Results: To implement the DCG (I) initiative 
PSUR program, one PSUR committee, one drug safety review panel and one Delphi 
panel for PSUR system assessment has been constituted. Drug safety reporting and 
assessment tools are prepared and validated. A manual reporting system of drug 
safety has been set up and one link on hospital intranet website will be very soon 
available for online drug safety reporting through each ward and departments of 
hospital. Necessary training on drug safety reporting is provided to all health care 
professionals. Online hospital information services are in use to track the prescrip-
tion of these drugs to the in-patients and then, these patients are extensively fol-
lowed for any drug related problem during their hospital stay. All the associated drug 
safety reports routed through wards to PSUR work station. The collected reports are 
assessed and coded using various scales, tools and softwares, e. g. Naranjo Scale, 
Hartwig severity scale and MedDRA coding software etc. PSUR system functioning 
in the hospital is assessed at regular time intervals through tool which is prepared 
and validated using Delphi technique. So far, since its inception two PSURs has 
been successfully submitted to DCG (I) at six months regular interval and third one 
is ready to report for next phase. cOnclusiOns: The present pioneering hospital 
based PSUR setup will create an environment for healthy safety reporting and helps 
the regulatory authorities for safety related decisions.
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Objectives: To study assessment and control the quality and the safety of hospi-
tals in Mongolia. MethOds: The research has been conducted by cross-sectional 
study by collecting information according to the quantitative and qualitative 
method. Results: In order to increase the quality and safety at the primary level 
hospitals the activity of special supporting (80.6%) and quality team control (66.7%) 
has been implemented, though, insufficient financing (33.3%) and professionals in 
quality control (19.4%) as well as special supporting activity has not been imple-
mented (91.7%). The special supporting activity (87.0%) has been implemented 
(p< 0.05) in the secondary level hospitals to increase the quality and safety, though, 
financing is insufficient (39.1%). The quality is conceptual idea, even though, this 
is a value that always could be felt and existed. The supporting activity (87.0%) and 
quality team (68.4%) are implemented (p< 0.05) to develop the quality in the tertiary 
level hospitals, however, other activities that develop quality are not implemented. 
The participants in the study answered about the challenging issues are high at all 
hospital levels, such as long queue to receive health service (54.5%-76.5%), overload 
in the hospital (67.6%-81.8%) and referral between hospitals (45.5% -72.2%) as well 
as hospital professionals are susceptible to illness (31.3%-52.2%). cOnclusiOns: 
Policy on quality and other related strategic documents are established 60-70% 
in the hospitals. Determination of health care and “determination of specialized 
health care standard through the diagnosis of the care” are insufficient at all level.
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Objectives: The purpose of the study was identifying the main problems of improv-
ing health care quality, organizational safety and human resource. MethOds: 
Questionnaire with 15 questions to study human resource potency. Financial state-
ment balance of 2007 and 2012. Questionnaire with 12 questions to study medical 
equipments potency Observational lists of internal and external environment safety 
of the hospitals Results: Totally 214 medical professionals were participated in 
the research: medical doctors 85 (39%), nurses 73 (34%), administration staff 16 (7%), 
and other staff 40 (19%). In 2007-2012 hospitals’ funding were increased up to 80%, 
whereas the number of birth increased up to 121%, number of surgeries increased up 
to 26% and number of inpatient clients up to 19%. It’s important to confirm the work 
position for medical equipment specialists and engineers according to the demands 
of medical equipment. cOnclusiOns: It is concluded that there is increasing need 
of consideration on the number of nurses, doctors and other health professionals. 
The result showed that it is urgent to run policy to assess the employees’ skills and 
supporting, appraising system should be open for everybody. Therefore 25% of the 
employees don’t recognize the organization mission, security policy and the deci-
sion making system is highly relevant to money. Amount of funding has improved 
but it still inadequate. Funding is still inadequate even it has improved between 
2007-2012. Domestic and foreign training is not enough for medical equipment 
specialists and engineers. Medical equipment technician’s skills are not adequate. 
Medical professionals’ knowledge about external and internal environment secu-
rity are ineffective. Hospitals external conditions got worse to 27% and internal 
